QURE (52) NBTX (52) STOK (59) CMPS (37) ⌘ Pro Terminal →

Kailera Therapeutics Inc. (KLRA) — RQD Stock Rating Cockpit

$13.41 -0.07% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $13.38

Kailera Therapeutics Inc. (KLRA) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY) →

ROARABLE D • SELL / AVOID Cap $1.74B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $13.38 (-0.20%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 1.2% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY • 49.3% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-3.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KLRA)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (50/100 Composite)

🔍 WHY KLRA SCORES 50/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (26% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (20% of score)

SEC XBRL FY 2025 (10-K): 1.2% FCF Margin ($48.7M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$11.61-3.1% Next Q

Q2 (-2Q)

Grade D$11.25+14.2% Next Q

Q3 (-1Q)

Grade D$12.85+4.4% Next Q

Current

Grade D$13.41-1.4% Hist 90D α

Trajectory: D (42) → D (50)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a KLRA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While KLRA currently carries a cautious 50/100 (D) rating due to Whale & Options Positioning (8/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($13.29) and Max Pain ($14.08) forces dealer call-delta covering toward $29.64.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KLRA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “KLRA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 50%NO 50%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

52.430 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE20% OF RANGE

L: $10$13.41H: $28

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 10 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 17 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 23 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on KLRA

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (50)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (45)

17/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like KLRA

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KLRA)

✓Walkthrough of KLRA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

KLRA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -46.36%▼ DESCENDING CHANNEL

2026-10-30O $13.27H $13.41L $12.53C $13.41VOL 868.4K

RES: $20.06SUP: $8.25SMA50: $13.29SMA200: $17.98

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KLRA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KLRA Butterfly Map → + Track KLRA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on KLRA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KLRA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for KLRA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KLRA)

Health Care Rank #342 of 1016 ⚔️ QURE vs KLRA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KLRA vs. QURE, NBTX, STOK, CMPS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Kailera Therapeutics Inc. (KLRA) ranks #342 by composite RQD confidence (50/100, grade D) and #282 by equity capitalization ($1.74B). Within this direct 5-issuer industry benchmark cohort, KLRA leads on earnings valuation at N/A trailing P/E, while STOK leads on capital efficiency and profitability with -6.1% ROIC and — gross margin. STOK currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with KLRA at 50/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
KLRA ACTIVE Kailera Therapeutics Inc.	D	50/100	—	—	—	-0.07%	$1.74B	Benchmark Subject
QURE uniQure N.V.	D+	52/100	—	—	-35.0%	+1.32%	$1.75B	/qure-vs-klra →
NBTX Nanobiotix S.A.	D+	52/100	—	—	—	-0.53%	$1.72B	/nbtx-vs-klra →
STOK Stoke Therapeutics Inc.	C-	59/100	—	—	-6.1%	-0.23%	$1.70B	/stok-vs-klra →
CMPS COMPASS Pathways Plc American Depository Shares	D-	37/100	—	—	-35.0%	-0.73%	$1.69B	/cmps-vs-klra →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002096997

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Kailera Therapeutics Inc. (KLRA) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, KLRA closed FY2025 with $692.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$692.3M	—

3. KLRA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KLRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Kailera Therapeutics Inc. (NASDAQ: KLRA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $13.41 (-0.07% 1D, market cap $1.74B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, KLRA ranks #342 in composite RQD confidence.

How does KLRA compare to QURE and NBTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KLRA carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, QURE (uniQure N.V.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC -35.0%, cap $1.75B) and NBTX (Nanobiotix S.A.) posts a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $1.72B). Among the 5-stock peer group, KLRA leads on earnings multiple (N/A) while STOK leads on capital efficiency (-6.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KLRA?

Per KLRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002096997), Kailera Therapeutics Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $692.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KLRA trading relative to its 50-day, 200-day, and 52-week technical levels?

KLRA last traded at $13.41 (-0.07% on volume of 1,044,500 shares), positioning the stock +0.90% above its 50-day simple moving average ($13.29) and -25.42% below its 200-day simple moving average ($17.98). Across its 52-week range of $9.76 to $28.23, KLRA sits at the 19.8% percentile with a 14-day RSI of 52.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($11.73 to $15.09).

KLRA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell KLRA stock right now?

Kailera Therapeutics Inc. (KLRA) currently earns a Roarable Rating of D (Sell — SELL) with 50/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

What is KLRA's 12-month price target and RQD AI Jury consensus?

KLRA's 12-month base price target is $12.93 (range $10.09 to $29.64), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: KLRA RQD Cockpit KLRA 12M Forecast KLRA Earnings & Move KLRA Dividends & DRIP KLRA Insiders & 13F KLRA Whale Options KLRA Profit Sankey KLRA News & Why